Is RedHill Biopharma Ltd. (RDHL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.6% / 30% | 98.2% / 30% | 75.8% / 30% | 1.65% / 5% | ✗ NOT HALAL |
| DJIM | 7.6% / 33% | 98.2% / 33% | 75.8% / 33% | 1.65% / 5% | ✗ NOT HALAL |
| MSCI | 2.0% / 33% | 25.6% / 33% | 19.8% / 33% | 1.65% / 5% | ✓ HALAL |
| S&P | 7.6% / 33% | 98.2% / 33% | 75.8% / 33% | 1.65% / 5% | ✗ NOT HALAL |
| FTSE | 2.0% / 33% | 25.6% / 33% | 19.8% / 50% | 1.65% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 64.4% | |
| Operating Margin | -107.3% | |
| Net Margin | -97.5% | |
| Return on Assets (ROA) | -25.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$9M |
| Free Cash Flow | -$9M |
| Total Debt | $356,000 |
| Current Ratio | 0.6 |
| Total Assets | $18M |
Price & Trading
| Last Close | $0.79 |
| 50-Day MA | $1.03 |
| 200-Day MA | $1.39 |
| Avg Volume | 494K |
| Beta | 5.0 |
|
52-Week Range
$0.75
| |
About RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is RedHill Biopharma Ltd. (RDHL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), RedHill Biopharma Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is RedHill Biopharma Ltd.'s debt ratio?
RedHill Biopharma Ltd.'s debt ratio is 7.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.0%.
What are RedHill Biopharma Ltd.'s key financial metrics?
RedHill Biopharma Ltd. has a market capitalization of $4M, trailing P/E ratio of inf, and revenue of $8M. The company maintains a gross margin of 64.4% and a net margin of -97.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.